Market Place
Sourcing Support
IMUNON Prices $7.0M Direct Offering Under NASDAQ Rules
30 Dec 2025 //
GLOBENEWSWIRE
Imunon Restores Nasdaq Minimum Bid Price Compliance
28 Aug 2025 //
GLOBENEWSWIRE
Imunon Reports Q2 2025 Financials Result, Updates on Business
05 Aug 2025 //
GLOBENEWSWIRE
IMUNON Increases Stock Dividend, Enhances Shareholder Value
28 Jul 2025 //
GLOBENEWSWIRE
Nasdaq Extends IMUNON`s Listing for Compliance Plan Completion
15 Jul 2025 //
GLOBENEWSWIRE
Imunon to Present at Zacks SCR Life Sciences Forum on June 12
05 Jun 2025 //
GLOBENEWSWIRE
Imunon CEO Recaps Clinical Achievements and Fundamentals
02 Jun 2025 //
GLOBENEWSWIRE
Imunon Announces $9.75M Private Placement Under Nasdaq Rules
23 May 2025 //
GLOBENEWSWIRE
IMUNON Reports 2024 Financial Results and Business Update
27 Feb 2025 //
GLOBENEWSWIRE
Imunon to Hold Q3 2024 Results Conference Call on Nov 7
31 Oct 2024 //
GLOBENEWSWIRE
IMUNON To Hold Q2 2024 Financial Results Call On August 14
07 Aug 2024 //
GLOBENEWSWIRE
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study in Ovarian Cancer
24 Jun 2024 //
GLOBENEWSWIRE
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
13 May 2024 //
GLOBENEWSWIRE
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
08 May 2024 //
GLOBENEWSWIRE
IMUNON Reports 2023 Financial Results and Provides Business Update
28 Mar 2024 //
GLOBENEWSWIRE
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
25 Mar 2024 //
GLOBENEWSWIRE
IMUNON Announces Leadership Change
12 Mar 2024 //
GLOBENEWSWIRE
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer
11 Dec 2023 //
GLOBENEWSWIRE
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion
19 Oct 2023 //
GLOBENEWSWIRE
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
06 Oct 2023 //
GLOBENEWSWIRE
IMUNON Reports Overall Survival Data in Phase 1/2 OVATION 2 Study
28 Sep 2023 //
GLOBENEWSWIRE
IMUNON Releases Enterprise Video Highlighting the Company™s Mission
26 Sep 2023 //
GLOBENEWSWIRE
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
14 Aug 2023 //
GLOBENEWSWIRE
IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells
30 May 2023 //
GLOBENEWSWIRE
IMUNON Presents Poster at the American Association for Cancer Research
19 Apr 2023 //
GLOBENEWSWIRE
IMUNON Reports 2022 Financial Results and Provides Business Update
30 Mar 2023 //
GLOBENEWSWIRE
IMUNON to Hold Fourth Quarter 2022 Financial Results
23 Mar 2023 //
GLOBENEWSWIRE
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
21 Mar 2023 //
GLOBENEWSWIRE
IMUNON Announces Abstract Accepted for Presentation at American Association
15 Mar 2023 //
GLOBENEWSWIRE
IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses
12 Jan 2023 //
GLOBENEWSWIRE
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute
05 Jan 2023 //
GLOBENEWSWIRE
IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
14 Dec 2022 //
GLOBENEWSWIRE
IMUNON Presentation at World Vaccine & Immunotherapy Highlights PLACCINE
01 Dec 2022 //
GLOBENEWSWIRE
IMUNON to Participate in the A.G.P. Virtual Biotech Conference
22 Nov 2022 //
GLOBENEWSWIRE
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics
10 Nov 2022 //
GLOBENEWSWIRE
Imunon to Hold 3Q 2022 Financial Results and Business Update Conference Call
07 Nov 2022 //
GLOBENEWSWIRE
Celsion rebrands to Imunon to reflect immunotherapy plans
20 Sep 2022 //
FIERCEBIOTECH
Celsion Corporation Announces Company Name Change to Imunon, Inc.
19 Sep 2022 //
GLOBENEWSWIRE
Celsion’s Phase I/II ovarian cancer trial completes subject enrolment
16 Sep 2022 //
CLINICALTRIALSARENA
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1
15 Sep 2022 //
GLOBENEWSWIRE
Celsion Corporation Presentation Time at the H.C. Wainwright 24th
12 Sep 2022 //
GLOBENEWSWIRE
Celsion Corporation to Present at the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
01 Sep 2022 //
GLOBENEWSWIRE
Celsion Corporation Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Celsion Corporation to Hold Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Celsion Corp Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
19 Jul 2022 //
GLOBENEWSWIRE
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
19 Jul 2022 //
GLOBENEWSWIRE
Celsion Corporation Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Celsion Corp Highlights Pipeline Progress in Its Lead Development Candidates
10 May 2022 //
GLOBENEWSWIRE
Celsion Corporation to Hold First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During
21 Apr 2022 //
GLOBENEWSWIRE
Celsion, Medidata Present Findings of Synthetic Control Arm in Ovarian Cancer
14 Apr 2022 //
GLOBENEWSWIRE
Celsion Corp to Highlight PLACCINE Platform Technology During Oral Presentation
12 Apr 2022 //
GLOBENEWSWIRE
Celsion slides on $7 million common stock offering
06 Apr 2022 //
SEEKING ALPHA
Celsion and Medidata to Present Findings on Use of Synthetic Control Arm
06 Apr 2022 //
GLOBENEWSWIRE
CELSION CORPORATION ANNOUNCES $7.0M REGISTERED DIRECT OFFERING
06 Apr 2022 //
GLOBENEWSWIRE
Why Celsion Stock Is Surging Today
05 Apr 2022 //
BENZINGA
Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021
01 Apr 2022 //
GLOBENEWSWIRE
Celsion Corporation Reports 2021 Financial Results and Provides Business Update
31 Mar 2022 //
GLOBENEWSWIRE
